Summit Therapeutics Q2 2026: Cash $690.7M; HARMONi-6 OS benefit; PDUFA Nov 14

Summit Therapeutics Inc.

Cash and investments $690.7M at June 30, 2026; raised $230.8M via ATM in Q2 and $68.4M post-quarter.
GAAP net loss $215.7M ($0.28/share); Non-GAAP net loss $147.0M ($0.19/share) vs $86.9M ($0.12) in Q2 2025.
HARMONi updated OS: HR 0.76 in full ITT, consistent in western and Asian patients; BLA PDUFA Nov 14, 2026.
HARMONi-6 (Akeso) showed OS benefit over tislelizumab (HR 0.66, p=0.0017) in 1L squamous NSCLC.
Sold ridinilazole to Biossil for $500K upfront + up to $104.5M milestones; clinical collaborations with Arcus, RevMed, GSK.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.